Journal: Journal of Sport and Health Science

Article Title: Decorin, an exercise-induced secretory protein, is associated with improved prognosis in breast cancer patients but does not mediate anti-tumorigenic tissue crosstalk in mice

doi: 10.1016/j.jshs.2024.100991

Figure Lengend Snippet: Systemic delivery of recombinant decorin into SCID mice injected with MDA-MB-231-HM cells. SCID mice injected with the MDA-MB-231-HM cells into mammary pads received 2 different doses of recombinant decorin systemically. (A) Tumor volume, (B) metastatic burden, (C) plasma decorin levels, and (D) tumor decorin levels after the low-dose experiment. Mice were dosed every second day with 100 µg of recombinant decorin or an equal volume of saline (Control) ∼14 days post tumor-cell inoculation. (E) Tumor volume, (F) metastatic burden, (G) plasma decorin levels, and (H) tumor decorin levels after the high-dose experiment. Mice were dosed daily with 10 mg/kg body weight (∼2.5 times the dose of low-dose experiment) of recombinant decorin or an equal volume of saline (Control) ∼7 days post tumor-cell inoculation. Tumor volume was assessed by calliper measurement of primary tumor growth and calculated as (length × width )/2. Metastatic burden was assessed by bioluminescence imaging detection. Plasma decorin levels were measured by ELISA. Tumor decorin levels were measured by western blot using total protein normalization. Two AAV:Dcn gastrocnemius lysates from the overexpression experiments were used as positive controls. Statistical testing was done with two-way analyses of variance or mixed effects model for repeated measures or Student's t test. Data expressed as means ± SEM. ( n = 5–7 mice per group). A.U. = arbitrary unit; con = control; Dcn = decorin; ELISA = enzyme linked immunosorbent assay.

Article Snippet: The concentration of decorin was measured in EV-free plasma with enzyme linked immunosorbent assay (ELISA) (DuoSet, Cat# DY143; R&D Systems, Minneapolis, MN, USA).

Techniques: Recombinant, Injection, Clinical Proteomics, Saline, Control, Imaging, Enzyme-linked Immunosorbent Assay, Western Blot, Over Expression

Journal: Journal of clinical medicine

Article Title: High Plasma Osteopontin Levels Are Associated with Serious Post-Acute-COVID-19-Related Dyspnea.

doi: 10.3390/jcm13020392

Figure Lengend Snippet: Figure 1. Increased plasma OPN levels were associated with long COVID symptoms in patients previously hospitalized for COVID-19. OPN levels from 181 plasma samples obtained during follow- up visits from 122 previously hospitalized COVID-19 patients were compared in the absence and presence of any symptom at any visit, n = 74 vs. n = 107 (A); any symptom at visits occurred 90 days or more (late visits) post-symptom onset, n = 67 vs. n = 87 (B); dyspnea at any visit, n = 102 vs.n = 79, (C); and dyspnea at late visits, n = 91 vs. n = 63 (D). Data are presented as 5–95 whisker plots with median; * p < 0.05, ** p < 0.01. OPN: osteopontin.

Article Snippet: OPN levels were determined using a Human Osteopontin ELISA kit (catalog number DY 1433, R&D Systems, Minneapolis, MN, USA) [24].

Techniques: Clinical Proteomics, Whisker Assay

Journal: Journal of clinical medicine

Article Title: High Plasma Osteopontin Levels Are Associated with Serious Post-Acute-COVID-19-Related Dyspnea.

doi: 10.3390/jcm13020392

Figure Lengend Snippet: Figure 2. Increased plasma OPN levels were associated with severe post-acute COVID-19 seque- lae.OPN levels from 181 plasma samples obtained during follow-up visits from 122 previously hospitalized COVID-19 patients were compared in the absence and presence of a serious symptom combination (defined as at least one of the following: dyspnea, fatigue and muscular weakness) at any visit, n = 89 vs. n = 92 (A), or at visits occurred 90 days or more (late visits) post-symptom onset, n = 80 vs. n = 74 (B); dyspnea where m-MRC > 1 at any visit, n = 146 vs. n = 29 (C); and dyspnea where m-MRC > 1 at late visits, n = 126 vs. n = 23 (D). Data are presented as 5–95 whisker plots with median, ** p < 0.01, *** p < 0.001. OPN: osteopontin, m-MRC: modified Medical Research Council dyspnea scale.

Article Snippet: OPN levels were determined using a Human Osteopontin ELISA kit (catalog number DY 1433, R&D Systems, Minneapolis, MN, USA) [24].

Techniques: Clinical Proteomics, Whisker Assay, Modification

Journal: Journal of clinical medicine

Article Title: High Plasma Osteopontin Levels Are Associated with Serious Post-Acute-COVID-19-Related Dyspnea.

doi: 10.3390/jcm13020392

Figure Lengend Snippet: Figure 4. Increased plasma OPN levels, higher BMI and decreased EQ-VAS score at hospitaldischarge were associated with impaired quality of life. Multiple correlations were calculated (correlation matrixheat map) between patients’ clinical characteristics, EQ-VAS score at any visit and plasma OPN levels obtained from 122 patients during follow-up visits to identify various parameters linked to impaired quality of life after hospitalization for acute COVID-19. Significant correlations were the following: (a) EQ-VAS: OPN (p < 0.01), (b) EQ-VAS: EQ-VAS at discharge (p < 0.001), (c) EQ-VAS: BMI (p < 0.01), (d) OPN: days from symptom onset (p < 0.001), (e) age: CCI (p < 0.001), (f) age: BMI (p < 0.05) and(g) CCI: BMI (p < 0.05). For all correlations, Spearman’s coefficient was calculated. EQ-VAS: visual analog scale score of EQ-5D-5L, EQ-5D-5L: European quality of life self-assessed questionnaire, OPN: osteopontin, CCI: Charlson comorbidity index, BMI: body mass index.

Article Snippet: OPN levels were determined using a Human Osteopontin ELISA kit (catalog number DY 1433, R&D Systems, Minneapolis, MN, USA) [24].

Techniques: Clinical Proteomics